Cannabidiol (CBD) is projected to be the next big ingredient, and the market for CBD-infused products is a high-growth opportunity. At the same time, CBD and other bio-actives from hemp involve complexities - formulation, supply chain and regulatory issues - that consumer product companies must address.
To help organizations understand the opportunity of CBD, RTI Innovation Advisors hosted an on-demand webinar “Navigating the science and complexity of cannabinoids' health and wellness claims.”
View the on-demand webinar, during which Lawrence Blume, Ph.D.
About Our Host
Over the last decade, Lawrence Blume, Ph.D. has applied his background in cannabinoid physiology and pharmacology towards novel commercial applications in the medical, CPG, and food and beverage space. Dr. Blume’s research on modulation of cannabinoid receptor activity has led to new insights and strategies for the treatment of central nervous system and other cannabis-related disorders. Lawrence continues to support commercialization and growth for emerging cannabinoid technologies, including the development of novel cell lines, viral vectors and delivery platforms.
A lead advisor for our food science and biotechnology innovation, Lawrence brings extensive experience leading technology-focused opportunity forecasts in support of competitive advantage, product differentiation, and commercialization strategies for C-level executives at companies ranging from early start-ups to Fortune 500s. He’s helped life science, food & beverage and consumer goods companies develop technical insights and business models that unlock and yield disruptive innovation in core products and markets.
Lawrence received a Ph.D. in Physiology & Pharmacology from Wake Forest School of Medicine and a B.S. in Biology with a minor in Biochemistry from Duquesne University.